• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aspira Women's Health Inc.

    11/14/24 3:23:57 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AWH alert in real time by email
    SC 13G 1 armistice-awh093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Aspira Women’s Health Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    04537Y208

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  04537Y208
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,256,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,256,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,256,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.76%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  04537Y208
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,256,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,256,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,256,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.76%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 04537Y208
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Aspira Women’s Health Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    12117 Bee Caves Road, Building III, Suite 100

    Austin, Texas 78738

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    04537Y208

     

    CUSIP No.  04537Y208
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 04537Y208
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 1,256,000

    Steven Boyd - 1,256,000   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 7.76%

    Steven Boyd - 7.76% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 1,256,000

    Steven Boyd - 1,256,000  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 1,256,000

    Steven Boyd - 1,256,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 04537Y208
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 04537Y208
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $AWH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AWH

    DatePrice TargetRatingAnalyst
    1/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AWH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

      Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

      1/10/25 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

      AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

      12/3/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

      Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00

      1/12/22 7:53:25 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Truist Securities initiated coverage on Aspira Womens Health with a new price target

      Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00

      3/29/21 7:32:28 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

      Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00

      1/29/21 6:12:39 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Leadership Updates

    Live Leadership Updates

    See more
    • Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

      AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

      12/16/24 8:45:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

      AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

      9/5/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

      AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

      7/29/24 9:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/28/25 7:19:40 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Hundorfean Cynthia D

      3 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/24/25 9:41:23 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      4/2/25 8:23:47 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      7/11/24 5:15:45 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/18/24 4:12:21 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

      4 - Aspira Women's Health Inc. (0000926617) (Issuer)

      6/3/24 5:30:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aspira Women's Health Inc.

      SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)

      11/14/24 3:23:57 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      7/11/24 5:14:26 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

      SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

      6/18/24 4:13:01 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    Financials

    Live finance-specific insights

    See more
    • Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

      Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

      11/14/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

      AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

      11/4/24 8:00:00 AM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

      AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

      7/31/24 4:05:00 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AWH
    SEC Filings

    See more
    • Amendment: SEC Form S-1/A filed by Aspira Women's Health Inc.

      S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/30/25 8:10:19 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEFR14A filed by Aspira Women's Health Inc.

      DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)

      4/22/25 4:05:41 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Aspira Women's Health Inc. (0000926617) (Filer)

      4/16/25 5:07:30 PM ET
      $AWH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care